Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
VZ$46.71+0.54(+1.17%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETAAPL$354.10+4.59(+1.31%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$217.02+17.56(+8.80%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.25+1.93(+0.76%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETAAPL$354.10+4.59(+1.31%)Apple: Demand Is Not The Problem7:54:50 AM ETMCD$281.93+1.71(+0.61%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.06-4.64(-2.70%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.00+1.20(+0.22%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$154.90-18.29(-10.56%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$97.22+1.34(+1.40%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ETQCOM$154.90-18.29(-10.56%)Qualcomm Q4: This Dip Is Not The One To Buy Yet7:45:04 AM ETAXP$337.50+4.88(+1.47%)American Express vs. PayPal: Which Financial Stock Is a Better Buy for 2027?7:45:01 AM ETSPCX$132.36-3.56(-2.62%)Stack Capital Group Inc. Reports Q3-2026 Financial Results7:45:00 AM ETCOP$139.45+2.51(+1.83%)BUZZ-ConocoPhillips rises on Q3 profit beat7:40:48 AM ETTGT$165.25+2.20(+1.35%)Target Looks More Attractive Than You'd Think7:31:07 AM ETCOP$139.45+2.51(+1.83%)UPDATE 2-ConocoPhillips beats estimates on higher oil prices, raises dividend7:30:23 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$635.50+5.50(+0.87%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$137.45-0.06(-0.04%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$354.10+4.59(+1.31%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETTSLA$376.25-8.94(-2.32%)Ferrari vs. Tesla: Can the Luce Outsell the Roadster?7:18:00 AM ETMU$757.79-37.67(-4.74%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$557.00+1.20(+0.22%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$354.10+4.59(+1.31%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ET

FATE · NASDAQ

Fate Therapeutics, Inc.

$2.07 -0.03 (-1.19%)

Company overview

Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders globally. Its NK- and T-cell immuno-oncology programs in development include FT516 for acute myeloid leukemia and B-cell lymphoma; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538 for acute myeloid leukemia and multiple myeloma; FT576 for multiple myeloma; FT819 for hematologic malignancies and solid tumors; FT536 for solid tumors; and FT500 for advanced solid tumors. The company has collaboration agreements with Ono Pharmaceutical for developing two off-the-shelf iPSC-derived CAR T-cell product candidates; with Juno Therapeutics for identifying small molecule modulators to enhance engineered T-cell immunotherapies; and with Janssen Biotech.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$241M
Employees
181
Headquarters
San Diego, CA
Website
fatetherapeutics.com
CEO
Bahram Valamehr
Listed
October 1, 2013
P/E
-1.90
Dividend yield
0.00%

Company financials

Revenue
$6.3M
Gross profit
$3.4M
Operating income
-$139M
EBITDA
-$122M
Net income
-$130M
EPS
-$1.09
Total assets
$285M
Total debt
$76.8M
Gross margin
53.80%
Net margin
-2,056.79%
Earnings yield
-52.66%

Revenue segmentation

By product (FY 2023)
By region (FY 2023)

No geographic segmentation.

Showing FY 2023

Price chart

1.461.922.382.843.30
FATE 1D NASDAQ O2.05H2.10L2.03C2.10+0.06 (+2.70%)Vol629.06K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
FATEFate Therapeutics, Inc. Stock news Fate Therapeutics Q3 net loss narrows as expenses fall Reuters
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Reports New Employee Inducement Awards GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Announces Receipt of California Institute GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Selected for Four Presentations GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics to Participate in Fireside Chat at the GlobeNewswire
FATEFate Therapeutics, Inc. Stock news BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE Defense World
FATEFate Therapeutics, Inc. Stock news Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead Seeking Alpha
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis GlobeNewswire
FATEFate Therapeutics, Inc. Stock news Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates GlobeNewswire
FATEFate Therapeutics, Inc. Stock news FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says Fox Business
FATEFate Therapeutics, Inc. Press release Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate GlobeNewswire
FATEFate Therapeutics, Inc. Stock news Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting GlobeNewswire
FATEFate Therapeutics, Inc. Press release Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting GlobeNewswire
See more
FAQ

Questions about Fate Therapeutics, Inc.

What does Fate Therapeutics, Inc. do?
Fate Therapeutics is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies for cancer and immune disorders globally. Its NK- and T-cell immuno-oncology programs in development include FT516 for acute myeloid leukemia and B-cell lymphoma; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538 for acute myeloid leukemia and multiple myeloma; FT576 for multiple myeloma; FT819 for hematologic malignancies and solid tumors; FT536 for solid tumors; and FT500 for advanced solid tumors. The company has collaboration agreements with Ono Pharmaceutical for developing two off-the-shelf iPSC-derived CAR T-cell product candidates; with Juno Therapeutics for identifying small molecule modulators to enhance engineered T-cell immunotherapies; and with Janssen Biotech.
What is FATE's market cap?
Fate Therapeutics, Inc. (FATE) is a listed stock with a live quote. The latest market cap on this page is $241M.
Where is Fate Therapeutics, Inc. headquartered?
Fate Therapeutics, Inc. is headquartered in San Diego, CA.
How do I get FATE news from the API?
Call GET /v1/news?tickers=FATE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does FATE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for FATE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the FATE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs